Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANIP with free AI briefings, catalyst countdowns, and dilution alerts.

ANIP · ANI PHARMACEUTICALS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$420.8M Cash on Hand
CF+ Cash Runway
Follow ANIP by email Get an email when ANIP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANIP, unsubscribe in one click. Privacy

📣 What ANIP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Purified Cortophin Gel 80 U Gout Arthritis Phase 4 · NCT07346079 Recruiting
Purified Cortophin Gel, 40 U Gout Arthritis Phase 4 · NCT07346079 Recruiting
Fluocinolone Acetonide Uveitis Phase 3 · NCT05486468 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANIP holds $420.8M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANIP files for a raise →

👥 Who Owns ANIP

Insiders 4.1% Institutions (412 holders) 95.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 2,899,843 11.87% 2026-06-30
Nikhil Lalwani
PRESIDENT & CEO, Director
Insider 333,689 1.37% 2026-10-15
Stephen P. Carey
SVP & CFO · +3,313 options
Insider 166,143 0.68% 2026-10-29
Christopher Mutz
HEAD OF RARE DISEASE
Insider 91,309 0.37% 2026-03-13
Ori Gutwerg
SVP, GENERICS
Insider 75,534 0.31% 2026-08-10
Meredith Cook
SR. VP, GENERAL COUNSEL & SEC.
Insider 72,924 0.30% 2026-11-13
Krista Davis
SVP, CHIEF HR OFFICER
Insider 51,946 0.21% 2026-03-06
Thomas Haughey
Director
Insider 38,878 0.16% 2026-05-21
Patrick D Walsh
Director
Insider 38,432 0.16% 2026-05-11
Thomas Andrew Rowland
SVP, HEAD - ESTABLISHED BRANDS
Insider 38,271 0.16% 2026-05-12
Renee P Tannenbaum
Director
Insider 29,514 0.12% 2026-05-21
Antonio R Pera
Director
Insider 27,017 0.11% 2026-05-21

Share count 24,422,240 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ANIP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANIP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.